Latest Multiple myeloma Stories
Presentations Including Pivotal Data on Kyprolis® and Blinatumomab, a BiTE® Immunotherapy, Demonstrate Company's Continued Commitment to Developing Treatments for Difficult-to-Treat Blood Cancers THOUSAND
- Note: This release corresponds to ASH abstracts 22, 31, 78, 84, 176, 327, 505, 2096, 2312, 3448, 3474, 4454, 4469, 4680 RARITAN, N.J., Nov.
MOSCOW, October 28, 2014 /PRNewswire/ -- Osteros Biomedica Ltd., a joint venture company of Maxwell Biotech Group and MBC Pharma Inc., and formed with the participation
BURLINGAME, Calif., Sept.
A*STAR scientists find new targets for modulating antibody response Singapore, Sept 1, 2014 - (ACN Newswire) - Scientists from A*STAR's
WHITE PLAINS, N.Y., Aug.
Favourite aunt inspires five marathon-run to get Canadians talking about hope for her incurable blood cancer EDMONTON, Aug.
THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.
Kyprolis Helped Patients Live 8.7 Months Longer Without Their Disease Worsening THOUSAND OAKS, Calif. and SOUTH SAN FRANCISCO, Calif., Aug.
- The governor of a province or people.